Trastuzumab: A picky partner?

Heather L. McArthur; Clifford A. Hudis

doi:10.1158/1078-0432.CCR-09-1917

Trastuzumab: A picky partner?

Heather L. McArthur, Clifford A. Hudis

Research output: Contribution to journal › Comment/debate › peer-review

3 Scopus citations

Abstract

Preclinical and clinical models of HER2-positive breast cancer show that human epidermal growth factor receptor 2 (HER2)-targeted therapy with trastuzumab adds significant benefits and modest risks to conventional cytotoxic therapies. Building on this advance will likely depend on elucidation of relevant signaling pathways and mechanisms of action for effective HER2-targeted therapies.

Original language	English (US)
Pages (from-to)	6311-6313
Number of pages	3
Journal	Clinical Cancer Research
Volume	15
Issue number	20
DOIs	https://doi.org/10.1158/1078-0432.CCR-09-1917
State	Published - Oct 15 2009
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-09-1917

Cite this

@article{6b1b7357b646457b827a3892633a0043,

title = "Trastuzumab: A picky partner?",

abstract = "Preclinical and clinical models of HER2-positive breast cancer show that human epidermal growth factor receptor 2 (HER2)-targeted therapy with trastuzumab adds significant benefits and modest risks to conventional cytotoxic therapies. Building on this advance will likely depend on elucidation of relevant signaling pathways and mechanisms of action for effective HER2-targeted therapies.",

author = "McArthur, {Heather L.} and Hudis, {Clifford A.}",

year = "2009",

month = oct,

day = "15",

doi = "10.1158/1078-0432.CCR-09-1917",

language = "English (US)",

volume = "15",

pages = "6311--6313",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "20",

}

TY - JOUR

T1 - Trastuzumab

T2 - A picky partner?

AU - McArthur, Heather L.

AU - Hudis, Clifford A.

PY - 2009/10/15

Y1 - 2009/10/15

N2 - Preclinical and clinical models of HER2-positive breast cancer show that human epidermal growth factor receptor 2 (HER2)-targeted therapy with trastuzumab adds significant benefits and modest risks to conventional cytotoxic therapies. Building on this advance will likely depend on elucidation of relevant signaling pathways and mechanisms of action for effective HER2-targeted therapies.

AB - Preclinical and clinical models of HER2-positive breast cancer show that human epidermal growth factor receptor 2 (HER2)-targeted therapy with trastuzumab adds significant benefits and modest risks to conventional cytotoxic therapies. Building on this advance will likely depend on elucidation of relevant signaling pathways and mechanisms of action for effective HER2-targeted therapies.

UR - http://www.scopus.com/inward/record.url?scp=70350223973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350223973&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-1917

DO - 10.1158/1078-0432.CCR-09-1917

M3 - Comment/debate

C2 - 19825955

AN - SCOPUS:70350223973

SN - 1078-0432

VL - 15

SP - 6311

EP - 6313

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 20

ER -

Trastuzumab: A picky partner?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this